



## Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294  
E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2024

Date: 27<sup>th</sup> June, 2024

**The President**  
Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

**The Vice President,**  
Listing Compliance Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051

ISIN: INE915B01019, INE915B07024  
BSE Scrip Code: 532305, 957989

NSE Symbol: INDSWFTLAB

**Subject: Outcome of the Meeting of the Board of Directors of Ind-Swift Laboratories Limited (“the Company”) in accordance with Regulation 30 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/ Ma’am,

With reference to the captioned subject and in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”), we wish to inform your good office that the Board of Directors of the Company at their meeting held today i.e. Thursday, June 27, 2024, has, inter alia, **considered and approved** the following businesses:

- I. Preferential Issue of up to **2,60,00,000 (Two Crores Sixty Lakhs) Fully Convertible Warrants (“Warrants”)** to certain entities belonging to “Promoter & Promoter Group” and “Non-promoter” category, at such price as may be determined by the Board / Committee of Directors in accordance with the provisions of Chapter V of Securities & Exchange Board of India (Issue of Capital & Disclosure) Regulations, 2015 (“**SEBI ICDR Regulations**”), as amended and applicable provisions of Companies Act, 2013 and rules made thereunder, for cash, to be convertible at the option of the warrant holder(s) in one or more tranches, within 18 (eighteen) months from the date of allotment into equivalent number of fully paid-up equity shares of face value of Rs. 10/- each, subject to shareholders’ approval and applicable regulatory authorities. The names of the proposed allottees are mentioned below:

S. No.	Name of the Proposed Allottees	Category	No. of Warrants proposed to be issued and allotted (up to)
1.	Essix Biosciences Limited	Promoter & Promoter Group	80,00,000
2.	HCP Investments	Non- Promoter	75,00,000
3.	Saral Incorporated VCC Sub Fund I	Non- Promoter	65,00,000
4.	Zeal Global Opportunities Fund	Non- Promoter	40,00,000
<b>TOTAL</b>			<b>2,60,00,000</b>



## Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
CIN No. L24232CH1995PLC015553



*Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the Preferential Allotment is enclosed as **Annexure A**.*

- II. Constituted a Preferential Issue Committee to finalize/approve the relevant documents and all other related matters with regard to the Preferential Issue, as may be deemed necessary.
- III. Took note that in terms of the provisions of Chapter V of the SEBI ICDR Regulations, the 'Relevant Date' for the purpose of determining the minimum issue price of the fully convertible warrants proposed to be issued to the above-mentioned allottees shall be Friday, 28<sup>th</sup> June, 2024 and thus, the issue price shall be determined in a meeting of the Board or Preferential Issue Committee on the said date.
- IV. Based upon the recommendation of Nomination and Remuneration Committee and subject to the approval of shareholders, approved the appointment of Sh. Param Bir Singh (DIN: 07616561) as an Independent Director of the Company for a period of five years commencing from June 27, 2024.  
The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as **Annexure B**.
- V. The draft notice of Postal Ballot for approval by the members of the Company and authorized the Board / Committee of Directors of the Company to finalize the same, upon determination of the Issue Price as per the provisions of Chapter V of SEBI ICDR Regulations, as amended.

The meeting of the Board of Directors commenced at 05:00 P.M. and concluded at 06:00 P.M.

The above information is also available on the website of the Company at [www.indswiflabs.com](http://www.indswiflabs.com).

You are requested to kindly take the same on your records.

Thanking you,  
Yours faithfully,

**For IND-SWIFT LABORATORIES LTD**

**PARDEEP VERMA  
VP-CORPORATE AFFAIRS &  
COMPANY SECRETARY**



**Encl.: As above**



## Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



### Annexure – A

#### **Details on Preferential Allotment in terms of SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023:**

S. No.	Particulars	Disclosures
1.	Type of securities proposed to be issued	Fully Convertible Warrants ('Warrants')
2.	Type of issuance	Preferential Issue
3.	Total number of securities proposed to be issued or total amount for which the securities will be issued	Issue and allotment of up to 2,60,00,000 Warrants at such issue price as maybe determined by the Board/ Committee of Directors in accordance with provisions of Chapter V of SEBI ICDR Regulations, as amended and applicable provisions of the Companies Act, 2013.
4.	Name and number of the Investor(s)	1. Essix Biosciences Limited 2. HCP Investments 3. Zeal Global Opportunities Fund 4. Saral Incorporated VCC Sub Fund 1
5.	Issue price	At such issue price as maybe determined by the Board/ Committee of Directors in accordance with provisions of Chapter V of SEBI ICDR Regulations, as amended and applicable provisions of the Companies Act, 2013.
6.	Tenure/ Conversion	Convertible into equivalent number of Equity Shares of Rs. 10/- each within a maximum period of 18 months from the date of allotment of such Warrants.
7.	Nature of Consideration (Whether cash or consideration other than cash)	Cash



## Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax : ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



### Annexure – B

#### Disclosure pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

S No	Particulars	Sh. Param Bir Singh
1	Director Identification Number (DIN)	07616561
2	Reason for change	Appointment as an Independent Director
3	Date of appointment & term of appointment	Appointed w.e.f., June 27, 2024 for a period of 5 years subject to approval of the members.
4	Disclosure of relationships between directors	No relationship exists with any other Directors/ KMP.
5	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/024 dated June 20, 2018 issued by the BSE and NSE, respectively.	In terms of BSE Circular bearing Reference No. LIST/COMP/14/2018-19 and NSE Circular bearing Reference No. NSE/CML/2018/24 dated June 20, 2018, we have received confirmation from Sh. Param Bir Singh that he is not debarred from accessing capital markets and / or restrained from holding the office of director by virtue of any order of the SEBI or any other such authority.
6	Brief Profile	<p>Sh. Param Bir Singh (Age 62 years) is MA in sociology from Punjab University, Chandigarh. He is a former Indian police officer of the 1988 Indian Police Service (IPS) batch. He has total experience of more than three decades of serving the country as a civil servant. He functioned as the Police Commissioner of Mumbai and the Director General (DG) of the Maharashtra Home Guard. He became Police Commissioner of Mumbai on 29<sup>th</sup> February 2020. He retired from the services as a Police Commissioner in June 2022.</p> <p>His previous posts include Director General (DG) of the Anti-Corruption Bureau (ACB), Police Commissioner of Thane, Superintendent of Police in Chandrapur and Bhandara, Deputy Commissioner of Police (Detection) in Mumbai, Additional Commissioner of Police in North-West Region in Mumbai, Additional Commissioner of Police in Anti-Terrorism Squad, and Additional Director General of Police (Law and Order).</p> <p>He has previously served as a director on the Board of the following government companies-</p> <ol style="list-style-type: none"><li>Maharashtra State Police Housing And Welfare Corporation Limited till March 17, 2021,</li><li>Thane Smart City Limited till July 30, 2018 and</li><li>Smart Kalyan Dombivli Development Corporation Limited till July 30, 2018.</li></ol> <p>He is currently serving as a director in Twenty Five Downtown Realty Limited since September, 2023.</p>